Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California. more
Time Frame | DAWN | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.31% | -2.12% | -3% |
1-Month Return | -6.09% | -3.42% | -0.73% |
3-Month Return | -13.46% | -11.13% | 2.87% |
6-Month Return | -2.52% | -5.74% | 7.17% |
1-Year Return | -7.65% | 3.97% | 25.31% |
3-Year Return | -28.79% | 1.05% | 28.38% |
5-Year Return | -50.6% | 34.37% | 81.89% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | - | 155.00K | 199.00K | 531.00K | 383.00K | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":29.19,"profit":true},{"date":"2021-12-31","value":37.48,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":72.13,"profit":true}] |
Gross Profit | - | (155.00K) | (199.00K) | (531.00K) | (383.00K) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-15500000,"profit":false},{"date":"2021-12-31","value":-19900000,"profit":false},{"date":"2022-12-31","value":-53100000,"profit":false},{"date":"2023-12-31","value":-38300000,"profit":false}] |
Gross Margin | - | (Infinity%) | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 14.90M | 13.78M | 72.74M | 146.91M | 206.06M | [{"date":"2019-12-31","value":7.23,"profit":true},{"date":"2020-12-31","value":6.69,"profit":true},{"date":"2021-12-31","value":35.3,"profit":true},{"date":"2022-12-31","value":71.29,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (14.90M) | (13.78M) | (72.74M) | (146.91M) | (206.06M) | [{"date":"2019-12-31","value":-1490500000,"profit":false},{"date":"2020-12-31","value":-1378200000,"profit":false},{"date":"2021-12-31","value":-7274300000,"profit":false},{"date":"2022-12-31","value":-14690900000,"profit":false},{"date":"2023-12-31","value":-20606400000,"profit":false}] |
Total Non-Operating Income/Expense | (4.16M) | (30.09M) | (7.00K) | 9.47M | - | [{"date":"2019-12-31","value":-43.87,"profit":false},{"date":"2020-12-31","value":-317.62,"profit":false},{"date":"2021-12-31","value":-0.07,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (16.98M) | (43.84M) | (72.75M) | (142.18M) | (188.92M) | [{"date":"2019-12-31","value":-1698400000,"profit":false},{"date":"2020-12-31","value":-4384300000,"profit":false},{"date":"2021-12-31","value":-7275400000,"profit":false},{"date":"2022-12-31","value":-14218100000,"profit":false},{"date":"2023-12-31","value":-18891700000,"profit":false}] |
Income Taxes | (2.27M) | (3.34M) | (2.31M) | (10.01M) | - | [{"date":"2019-12-31","value":-227300000,"profit":false},{"date":"2020-12-31","value":-333700000,"profit":false},{"date":"2021-12-31","value":-231200000,"profit":false},{"date":"2022-12-31","value":-1000500000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | (14.71M) | (40.51M) | (70.44M) | (132.18M) | - | [{"date":"2019-12-31","value":-1471100000,"profit":false},{"date":"2020-12-31","value":-4050600000,"profit":false},{"date":"2021-12-31","value":-7044200000,"profit":false},{"date":"2022-12-31","value":-13217600000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (16.98M) | (43.84M) | (72.75M) | (142.18M) | (188.92M) | [{"date":"2019-12-31","value":-1698400000,"profit":false},{"date":"2020-12-31","value":-4384300000,"profit":false},{"date":"2021-12-31","value":-7275400000,"profit":false},{"date":"2022-12-31","value":-14218100000,"profit":false},{"date":"2023-12-31","value":-18891700000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (14.71M) | (40.51M) | (70.44M) | (132.18M) | (188.92M) | [{"date":"2019-12-31","value":-1471100000,"profit":false},{"date":"2020-12-31","value":-4050600000,"profit":false},{"date":"2021-12-31","value":-7044200000,"profit":false},{"date":"2022-12-31","value":-13217600000,"profit":false},{"date":"2023-12-31","value":-18891700000,"profit":false}] |
EPS (Diluted) | (0.67) | (5.99) | (6.40) | (2.17) | (2.38) | [{"date":"2019-12-31","value":-67.2,"profit":false},{"date":"2020-12-31","value":-599.07,"profit":false},{"date":"2021-12-31","value":-640,"profit":false},{"date":"2022-12-31","value":-217,"profit":false},{"date":"2023-12-31","value":-238,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
DAWN | |
---|---|
Cash Ratio | 14.05 |
Current Ratio | 14.62 |
Quick Ratio | 14.55 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
DAWN | |
---|---|
ROA (LTM) | -25.43% |
ROE (LTM) | -17.84% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
DAWN | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.08 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.92 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
DAWN | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 12.65 |
P/B | 2.32 |
Price/FCF | NM |
EV/R | 7.19 |
EV/Ebitda | NM |
Day One Biopharmaceuticals Inc (DAWN) share price today is $12.79
Yes, Indians can buy shares of Day One Biopharmaceuticals Inc (DAWN) on Vested. To buy Day One Biopharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in DAWN stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Day One Biopharmaceuticals Inc (DAWN) via the Vested app. You can start investing in Day One Biopharmaceuticals Inc (DAWN) with a minimum investment of $1.
You can invest in shares of Day One Biopharmaceuticals Inc (DAWN) via Vested in three simple steps:
The 52-week high price of Day One Biopharmaceuticals Inc (DAWN) is $18.07. The 52-week low price of Day One Biopharmaceuticals Inc (DAWN) is $11.94.
The price-to-earnings (P/E) ratio of Day One Biopharmaceuticals Inc (DAWN) is
The price-to-book (P/B) ratio of Day One Biopharmaceuticals Inc (DAWN) is 2.32
The dividend yield of Day One Biopharmaceuticals Inc (DAWN) is 0.00%
The market capitalization of Day One Biopharmaceuticals Inc (DAWN) is $1.26B
The stock symbol (or ticker) of Day One Biopharmaceuticals Inc is DAWN